This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Lexicon's CEO Presents At Wedbush PacGrow 2012 Life Sciences Management Access Conference (Transcript)

Lexicon Pharmaceuticals, Inc. (LXRX)

Wedbush PacGrow 2012 Life Sciences Management Access Conference Transcript

August 14, 2012 10:55 AM ET


Dr. Arthur Sands - President and CEO


Liana Moussatos - Wedbush


Liana Moussatos - Wedbush

I guess we'll get started. I'm Liana Moussatos from Wedbush. Welcome to our Third Annual LS MAC Conference. Right now we have Dr. Arthur Sands, CEO of Lexicon Pharmaceuticals, who'll give us a corporate update. Dr. Sands?

Dr. Arthur Sands

Thank you, Leigh Ann. It's a pleasure to be with you today. I will be making certain forward-looking statements and so I'd like to refer you to our filings with the SEC regarding risk factors that affect our business and our pipeline. So, it's been a very exciting and very busy summer for Lexicon as we've received our data from our LX4211 Phase 2b trial in diabetes. And I'll spend most of the session today describing the data from that trial. But I'll also put in context of our broader development plan for LX4211 as we get ready to move into Phase 3 with that compound.

Now all the compounds of Lexicon derive from our genetics engine. Our mission for those of you who don't know is we're dedicated to developing truly breakthrough therapies for disease that are all targeted in nature that as we use genetics and gene knockout technology to define the target, and so all of our programs are genetically defined as targets. And then we have a medicinal chemistry group that develops small molecules for those targets. So our entire pipeline has been developed within this research engine with genetics at the beginning and then getting to small molecule development.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs